NIH Launches Vaccine Trial for Epstein-Barr Virus, Potential Relation to COVID-19 Shots? (VIDEO)

The National Institute of Allergy and Infectious Diseases (NIAID), Fraudci’s NIH department, announced the launch of an early-stage clinical trial for their Epstein-Barr virus (EBV) vaccine candidate.

Fauci is super excited about this gp350-Ferritin nanoparticle vaccine for Epstein-Barr Virushttps://t.co/CTpYoeZ5Or

— Underground(not-so-nice)courtlady (@Undergroundcou1) May 8, 2022

Contagion Live reported:

Phase 1 trials for the investigational, preventative vaccine will be conducted at the NIH Clinical Center in Bethesda, Maryland. This will be 1 of only 2 studies that have tested an EBV vaccine candidate in over a decade.

Trending: WSJ Report: President Trump Wants Buy Greenland!

Epstein-Barr virus is the primary cause of infectious mononucleosis, and may also cause certain cancers and autoimmune disorders. EBV is classified as a herpes virus and is one of the most common human viruses. It spreads very easily, primarily through saliva and other bodily fluids.

“A vaccine that could prevent or reduce the severity of infection with the Epstein-Barr virus could reduce the incidence of infectious mononucleosis and might also reduce the incidence of EBV-associated malignancies and autoimmune diseases,” said Anthony S. Fauci, MD, NIAID director and the White House chief medical adviser.

The NIH estimates there are 125000 infectious mononucleosis cases each year in the US alone. About 10% of these infected individuals will develop fatigue that can last over 6 months, and 1% develop severe complications like hepatitis, blood abnormalities, or neurologic problems.

The vaccine targets EBV glycoprotein gp350, found on the surface of the virus and virus-infected cells. EBV gp350 in also the primary target of neutralizing antibodies naturally produced by people infected with EBV.

The study will evaluate the safety and immunogenicity of the EBV gp350-Ferritin nanoparticle vaccine. The vaccine candidate was developed by the Laboratory of Infectious Diseases, in conjunction with NIAIDS’s Vaccine Research Center. The vaccine features a saponin-based Matrix-M adjuvant, which was developed by the biotechnology company Novavax.

Led by principal investigator Jessica Durkee-Shock, MD, of NIAID’s Laboratory of Infectious Diseases, the study will enroll 40 healthy volunteers aged 18-29 years old. Half will have evidence of a prior EBV infection, and half will have had no exposure to EBV. The participants will be given 3 50-microgram intramuscular injections of the vaccine. The second dose will be administered after 30 days, and the third dose 150 days after the second. Participants will be observed for 30-60 minutes after each injection. The trial is expected to last 4 years.

The Epstein-Barr virus, the key cause of mononucleosis and linked to some cancers and autoimmune diseases, is the target of a new early-stage NIAID vaccine trial. Read more: https://t.co/DSYuIpXtXG pic.twitter.com/dhOjgvpYcF

— NIAID News (@NIAIDNews) May 6, 2022

How could the COVID-19 shots potentially be linked to Epstein-Barr Virus?

The saying ‘those who create the sickness provide the cure’ rings true.

Check out this Rumble clip from Dr. Robert Malone:

What did he mention?

Epstein-Barr Virus?

Highly suspect if you ask me!